KR101540296B1 - 효소적 항암 요법 - Google Patents

효소적 항암 요법 Download PDF

Info

Publication number
KR101540296B1
KR101540296B1 KR1020097023239A KR20097023239A KR101540296B1 KR 101540296 B1 KR101540296 B1 KR 101540296B1 KR 1020097023239 A KR1020097023239 A KR 1020097023239A KR 20097023239 A KR20097023239 A KR 20097023239A KR 101540296 B1 KR101540296 B1 KR 101540296B1
Authority
KR
South Korea
Prior art keywords
adenosine deaminase
ada
tumor
composition
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097023239A
Other languages
English (en)
Korean (ko)
Other versions
KR20090130108A (ko
Inventor
데이비드 알. 필풀라
퓨자 새프라
Original Assignee
시그마-타우 레어 디지즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마-타우 레어 디지즈 리미티드 filed Critical 시그마-타우 레어 디지즈 리미티드
Publication of KR20090130108A publication Critical patent/KR20090130108A/ko
Application granted granted Critical
Publication of KR101540296B1 publication Critical patent/KR101540296B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020097023239A 2007-04-20 2008-04-18 효소적 항암 요법 Active KR101540296B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
US60/913,039 2007-04-20

Publications (2)

Publication Number Publication Date
KR20090130108A KR20090130108A (ko) 2009-12-17
KR101540296B1 true KR101540296B1 (ko) 2015-07-31

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023239A Active KR101540296B1 (ko) 2007-04-20 2008-04-18 효소적 항암 요법

Country Status (19)

Country Link
US (1) US8741283B2 (cg-RX-API-DMAC7.html)
EP (1) EP2147122B1 (cg-RX-API-DMAC7.html)
JP (1) JP5595904B2 (cg-RX-API-DMAC7.html)
KR (1) KR101540296B1 (cg-RX-API-DMAC7.html)
CN (1) CN101680039B (cg-RX-API-DMAC7.html)
BR (1) BRPI0810384B8 (cg-RX-API-DMAC7.html)
CA (1) CA2684749C (cg-RX-API-DMAC7.html)
CY (1) CY1117000T1 (cg-RX-API-DMAC7.html)
DK (1) DK2147122T3 (cg-RX-API-DMAC7.html)
ES (1) ES2507508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140947T1 (cg-RX-API-DMAC7.html)
IL (1) IL201593A (cg-RX-API-DMAC7.html)
MX (1) MX2009011320A (cg-RX-API-DMAC7.html)
NZ (1) NZ580980A (cg-RX-API-DMAC7.html)
PL (1) PL2147122T3 (cg-RX-API-DMAC7.html)
PT (1) PT2147122E (cg-RX-API-DMAC7.html)
SI (1) SI2147122T1 (cg-RX-API-DMAC7.html)
TW (1) TWI486169B (cg-RX-API-DMAC7.html)
WO (1) WO2008131163A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005333165B2 (en) 2004-11-12 2012-07-19 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2147116B1 (en) 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
EP3178932A1 (en) * 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
EP3426299A4 (en) * 2016-03-11 2019-10-16 University of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR TREATMENT OF TUMORS
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
US20240250753A1 (en) * 2022-10-10 2024-07-25 Berkeley Marine Robotics Inc. Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902588A (en) * 1994-06-24 1999-05-11 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
KR20050109956A (ko) * 2003-03-04 2005-11-22 브리스톨-마이어스 스큅 컴퍼니 아데노신 데아미나제 효소를 사용한 디데옥시이노신의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
AU2001297556A1 (en) * 2000-11-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU2002365360A1 (en) * 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CA2653061A1 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
CN101534861B (zh) 2006-09-15 2013-10-02 安佐制药股份有限公司 具有基于位阻酯的生物可降解连接基的聚环氧烷
WO2008083302A2 (en) * 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
EP2147116B1 (en) 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902588A (en) * 1994-06-24 1999-05-11 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
KR20050109956A (ko) * 2003-03-04 2005-11-22 브리스톨-마이어스 스큅 컴퍼니 아데노신 데아미나제 효소를 사용한 디데옥시이노신의 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eur J Pharmacol. 12;341(2-3):289-97 (1998. 2) *
Eur J Pharmacol. 12;341(2-3):289-97 (1998. 2)*

Also Published As

Publication number Publication date
CN101680039B (zh) 2016-08-24
EP2147122A4 (en) 2010-11-17
ES2507508T3 (es) 2014-10-15
WO2008131163A8 (en) 2010-01-28
RU2009142817A (ru) 2011-05-27
EP2147122B1 (en) 2014-07-16
BRPI0810384B1 (pt) 2021-02-02
CA2684749C (en) 2016-06-21
SI2147122T1 (sl) 2015-01-30
PL2147122T3 (pl) 2015-05-29
US20090047270A1 (en) 2009-02-19
BRPI0810384A2 (pt) 2014-11-04
US8741283B2 (en) 2014-06-03
CN101680039A (zh) 2010-03-24
TWI486169B (zh) 2015-06-01
CY1117000T1 (el) 2017-04-05
MX2009011320A (es) 2009-12-15
JP2010524968A (ja) 2010-07-22
KR20090130108A (ko) 2009-12-17
AU2008242791A1 (en) 2008-10-30
CA2684749A1 (en) 2008-10-30
HRP20140947T1 (hr) 2015-02-13
WO2008131163A1 (en) 2008-10-30
DK2147122T3 (da) 2014-10-13
TW200902051A (en) 2009-01-16
NZ580980A (en) 2012-04-27
PT2147122E (pt) 2014-10-15
JP5595904B2 (ja) 2014-09-24
BRPI0810384B8 (pt) 2021-05-25
IL201593A (en) 2017-07-31
IL201593A0 (en) 2010-05-31
EP2147122A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
KR101540296B1 (ko) 효소적 항암 요법
US8937048B2 (en) Anti-angiogenic compounds
AU2021225133A1 (en) Conjugates of an IL-2 moiety and a polymer
KR101499095B1 (ko) 안정한 재조합 아데노신 데아미나제
EA004789B1 (ru) Полимерные конъюгаты бета-1а-интерферона и их использование
US11752216B2 (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof
EA009289B1 (ru) ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕВРОПАТИИ С ИСПОЛЬЗОВАНИЕМ β-ИНТЕРФЕРОНА
CA2409679A1 (en) Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy
AU2008242791B2 (en) Enzymatic anticancer therapy
RU2481855C2 (ru) Ферментативная противоопухолевая терапия
HK1142634A (en) Enzymatic anticancer therapy
KR102746951B1 (ko) 경구 투여용 유전자 전달체 및 이를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
CN118497178A (zh) 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用
RU2486246C2 (ru) Стабильная рекомбинантная аденозиндеаминаза
HK40013258A (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof
HK1142639B (en) Stable recombinant adenosine deaminase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20110704

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120803

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141027

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150423

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150508

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150723

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150723

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150724

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220712

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250704

Start annual number: 11

End annual number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11